Clinical Trial Update: Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Status update on a completed Phase 1 trial evaluating the combination of panobinostat and carfilzomib in patients with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Farydak (panobinostat)
• Kyprolis (carfilzomib)

Snippet

Sponsor: Emory University | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED